Menu
Not yet recruiting NCT06849128

NeuroReAlign Therapy for Cognitive Rehabilitation in Patients with Stroke

No phase Interventional Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NeuroReAlign Therapy, Conventional cognitive training.
Who it may be relevant to
Registry conditions: Stroke. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of NeuroReAlign Therapy on Cognition in Patients with Stroke: a Randomized Controlled Trial

Overview

The goal of this randomized controlled trial is to investigate the effects of NeuroReAlign Therapy on cognition in stroke survivors in the chronic stage (\>6 months). The study will include male and female participants aged 18-70 years. The main questions it aims to answer are: Does NeuroReAlign Therapy improve cognition in stroke survivors compared to conventional physiotherapy? Researchers will compare NeuroReAlign Therapy to conventional cognitive therapy to determine its effects on cognition. Participants will: Undergo NeuroReAlign Therapy or conventional cognitive therapy for 4 weeks. Have their cognition evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Trail Making Test (TMT), Stroop Test, Digit Span Test, and Verbal Fluency Test (VFT). Complete outcome assessments at baseline and after the intervention (week 4).

Interventions

  • Other NeuroReAlign Therapy
    Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
  • Other Conventional cognitive training
    A conventional cognitive training protocol involves structured, repetitive exercises designed to enhance specific cognitive functions, such as memory, attention, executive function, and processing speed. These training programs are delivered through paper-and-pencil tasks, computer-based exercises, and therapist-guided activities. Tasks used include working memory exercises (e.g., digit span recall), attention training (e.g., Stroop test, visual scanning), problem-solving activities (e.g., Tower

Primary outcome measures

  • Montreal Cognitive Assessment (MoCA) [Time frame: At baseline (week 0) and post-intervention (week 4)]
Secondary outcome measures (5)
  • Mini-Mental State Examination (MMSE) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Trail Making Test (TMT) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Stroop Test [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Digit Span Test [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Verbal Fluency Test (VFT) [Time frame: At baseline (week 0) and post-intervention (week 4)]

Eligibility criteria

Inclusion criteria

  • Patients with ischemic or hemorrhagic stroke
  • Have a stroke more than 6 months
  • Age between 18 and 70

Exclusion criteria

  • Patients with severe cognitive impairments
  • Patients cannot walk independently

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06849128 · ADA/1100

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗